Omnicell Financials
OMCL Stock | USD 38.06 0.41 1.07% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 2.63 | 1.369 |
|
|
The essential information of the day-to-day investment outlook for Omnicell includes many different criteria found on its balance sheet. An individual investor should monitor Omnicell's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Omnicell.
Net Income |
|
Omnicell | Select Account or Indicator |
Omnicell Earnings Geography
Omnicell Stock Summary
Omnicell competes with HealthStream, National Research, Forian, Definitive Healthcare, and Evolent Health. Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California. Omnicell operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. It employs 4000 people.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US68213N1090 |
CUSIP | 68213N109 |
Location | California; U.S.A |
Business Address | 4220 North Freeway, |
Sector | Health Care Technology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.omnicell.com |
Phone | 877 415 9990 |
Currency | USD - US Dollar |
Omnicell Key Financial Ratios
Return On Equity | 0.0103 | ||||
Profit Margin | 0.01 % | ||||
Operating Margin | 0.04 % | ||||
Price To Sales | 1.60 X | ||||
Revenue | 1.11 B |
Omnicell Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 1.8B | 2.1B | 2.2B | 2.2B | 2.1B | 2.2B | |
Other Current Liab | 113.4M | 179.4M | 344.7M | 177.8M | 402.5M | 422.7M | |
Other Liab | 57.9M | 64.5M | 79.7M | 46.2M | 53.1M | 33.7M | |
Net Debt | 30.2M | 179.0M | 286.4M | 146.1M | 2.6M | 2.8M | |
Retained Earnings | 290.7M | 368.6M | 390.7M | 370.4M | 382.9M | 402.0M | |
Accounts Payable | 40.3M | 71.5M | 63.4M | 45.0M | 51.8M | 26.3M | |
Cash | 485.9M | 349.1M | 330.4M | 468.0M | 369.2M | 387.7M | |
Long Term Debt | 50M | 467.2M | 566.6M | 569.7M | 166.4M | 176.3M | |
Net Receivables | 190.1M | 240.9M | 299.5M | 263.9M | 256.4M | 269.2M | |
Inventory | 96.3M | 119.9M | 147.5M | 110.1M | 88.7M | 54.0M | |
Other Current Assets | 57.1M | 70.8M | 104.4M | 85.6M | 101.2M | 106.3M | |
Total Liab | 857.0M | 995.8M | 1.1B | 1.0B | 877.6M | 921.5M | |
Total Current Assets | 829.4M | 780.7M | 881.8M | 927.6M | 815.5M | 856.3M | |
Short Term Debt | (55.4M) | 501.1M | 10.8M | 10.5M | 12.1M | 11.5M | |
Common Stock | 53K | 54K | 55K | 56K | 57K | 54.2K | |
Other Assets | 100.7M | 268.5M | 225.6M | 139.0M | 159.8M | 167.8M | |
Good Will | 499.3M | 738.9M | 734.3M | 735.8M | 734.7M | 771.5M | |
Intangible Assets | 168.2M | 277.6M | 242.9M | 277.8M | 188.3M | 103.8M | |
Net Tangible Assets | 845.3M | 967.5M | 130.2M | 153.0M | 175.9M | 297.7M | |
Capital Surpluse | 780.9M | 920.4M | 1.0B | 1.0B | 1.2B | 729.3M |
Omnicell Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Interest Expense | 2.1M | 22.4M | 130K | 14.8M | 25.3M | 26.5M | |
Total Revenue | 892.2M | 1.1B | 1.3B | 1.1B | 1.1B | 1.2B | |
Gross Profit | 413.3M | 554.7M | 589.0M | 496.8M | 471.0M | 257.7M | |
Operating Income | 35.5M | 89.5M | (2.3M) | (34.9M) | 337K | 320.2K | |
Ebit | 35.5M | 89.5M | (2.3M) | (34.9M) | (40.1M) | (38.1M) | |
Research Development | 70.2M | 75.7M | 105.0M | 97.1M | 90.4M | 94.9M | |
Ebitda | 107.1M | 174.4M | 96.8M | (34.9M) | 337K | 320.2K | |
Cost Of Revenue | 478.9M | 577.4M | 707.0M | 650.3M | 641.2M | 673.3M | |
Income Before Tax | 29.3M | 66.0M | (2.5M) | (20.1M) | 25.6M | 19.1M | |
Net Income | 32.2M | 77.8M | 5.6M | (20.4M) | 12.5M | 17.6M | |
Income Tax Expense | (2.8M) | (11.8M) | (8.1M) | 263K | 13.1M | 13.7M | |
Tax Provision | (2.8M) | (11.8M) | (8.1M) | (2.7M) | 13.1M | 13.7M | |
Net Interest Income | (6.2M) | (23.5M) | (130K) | 12.8M | 25.3M | 26.5M |
Omnicell Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change To Inventory | 12.4M | (25.7M) | (30.1M) | 38.0M | 5.4M | 5.7M | |
Change In Cash | 362.7M | (134.3M) | (2.8M) | 148.1M | (102.4M) | (97.2M) | |
Free Cash Flow | 131.0M | 173.5M | 17.0M | 126.1M | 151.3M | 158.8M | |
Depreciation | 71.6M | 84.9M | 99.2M | 95.6M | 89.8M | 94.2M | |
Other Non Cash Items | 6.6M | 22.5M | 15.5M | 18.0M | 61.0M | 64.0M | |
Capital Expenditures | 54.9M | 58.3M | 60.7M | 55.0M | 36.5M | 25.8M | |
Net Income | 32.2M | 77.8M | 5.6M | (20.4M) | 12.5M | 17.6M | |
End Period Cash Flow | 489.9M | 355.6M | 352.8M | 501.0M | 398.6M | 418.5M | |
Investments | (279.9M) | (412.5M) | (58.7M) | (59.9M) | (52.8M) | (55.4M) | |
Change Receivables | (25.2M) | 34.0M | (37.6M) | (75.7M) | (68.1M) | (64.7M) | |
Change To Netincome | 33.2M | 38.4M | 50.3M | 31.6M | 36.4M | 21.5M |
Omnicell Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Omnicell's current stock value. Our valuation model uses many indicators to compare Omnicell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Omnicell competition to find correlations between indicators driving Omnicell's intrinsic value. More Info.Omnicell is regarded fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.28 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Omnicell is roughly 3.55 . At this time, Omnicell's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Omnicell by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Omnicell Systematic Risk
Omnicell's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Omnicell volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Omnicell correlated with the market. If Beta is less than 0 Omnicell generally moves in the opposite direction as compared to the market. If Omnicell Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Omnicell is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Omnicell is generally in the same direction as the market. If Beta > 1 Omnicell moves generally in the same direction as, but more than the movement of the benchmark.
Omnicell Thematic Clasifications
Omnicell is part of Computers investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Computers industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Computers industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Computers | View |
Today, most investors in Omnicell Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Omnicell's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Omnicell growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Omnicell March 1, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Omnicell help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Omnicell. We use our internally-developed statistical techniques to arrive at the intrinsic value of Omnicell based on widely used predictive technical indicators. In general, we focus on analyzing Omnicell Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Omnicell's daily price indicators and compare them against related drivers.
Information Ratio | (0.08) | |||
Maximum Drawdown | 17.78 | |||
Value At Risk | (3.17) | |||
Potential Upside | 3.19 |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Omnicell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Omnicell Stock please use our How to buy in Omnicell Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omnicell. If investors know Omnicell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omnicell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.558 | Earnings Share 0.27 | Revenue Per Share | Quarterly Revenue Growth 0.186 | Return On Assets |
The market value of Omnicell is measured differently than its book value, which is the value of Omnicell that is recorded on the company's balance sheet. Investors also form their own opinion of Omnicell's value that differs from its market value or its book value, called intrinsic value, which is Omnicell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omnicell's market value can be influenced by many factors that don't directly affect Omnicell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omnicell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Omnicell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omnicell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.